Caitlin Raymond: Granulocyte Transfusions for the Overworked Fellow
Caitlin Raymond, Assistant Professor of Pathology and Transfusion Medicine at University of Wisconsin-Madison, shared a post on Linkedin:
“New post: Granulocyte Transfusions for the Overworked Fellow.
Someone suggests granulocytes for your profoundly neutropenic, fungal-infected, not-responding patient. You nod. You place the consult. And somewhere in the back of your mind, a small voice asks: does this actually work?
That voice deserves an honest answer.
Here’s what the literature actually gives us:
- The biological rationale is sound. No neutrophils, no innate immune response. Supplementing from the outside makes mechanistic sense.
- The RING trial was the most rigorous attempt to test this — randomized, adequately powered, mortality endpoint. It didn’t show a survival benefit.
- But RING had a problem: delivered doses were consistently below what’s considered therapeutic. If you can’t reliably deliver the intervention, you can’t cleanly interpret the result.
- The amphotericin timing rule? Traced back to a single 1981 paper. Subsequent studies failed to replicate it. The practice outlived the evidence.
- The 1 × 10¹⁰ dose target is real — but collection yields are variable, and hitting it is not guaranteed even with G-CSF and dexamethasone stimulation.
We have not arrived at a definitive answer on whether granulocyte transfusions improve survival. We tried hard to find out. The best trial we have had a fatal flaw in its ability to deliver the intervention reliably.
Knowing the limits of the evidence is not a failure of clinical knowledge. It is the clinical knowledge.”

Other posts featuring Caitlin Raymond on Hemostasis Today.
-
Jul 12, 2026, 17:04Marc Carrier: EPCAT III Trial at ISTH 2026 Supports Aspirin Alone for VTE Prevention After Arthroplasty
-
Jul 12, 2026, 16:15Louise St. Germain Bannon: Global Collaboration Is Key to Turning Scientific Innovation Into Better Care
-
Jul 12, 2026, 16:10Marc Carrier: Major Scientific Highlight Confirms the Safety of the YEARS Algorithm at ISTH 2026
-
Jul 12, 2026, 16:01Joseph R. Shaw: Sharing New Insights into Antithrombotic Therapy and Thrombin Generation at ISTH 2026
-
Jul 12, 2026, 15:45Nathan Connell: Key Clinical Advances in Heavy Menstrual Bleeding and Postpartum Hemorrhage from ISTH 2026
-
Jul 12, 2026, 15:40Anne-Claire Duchez: Join Us at ISTH 2026 to Discover Our Latest Research and Meet the Team
-
Jul 12, 2026, 12:30Reduced-Dose DOACs in GI Malignancies: Toward Personalized Anticoagulation
-
Jul 12, 2026, 08:50Where the Hemophilia Community Comes Together at ISTH 2026 – EAHAD
-
Jul 12, 2026, 08:2210 Posts Not To Miss from ISTH 2026, Part 1